<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127595</url>
  </required_header>
  <id_info>
    <org_study_id>GEMOX</org_study_id>
    <nct_id>NCT00127595</nct_id>
  </id_info>
  <brief_title>Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract</brief_title>
  <official_title>A Phase II Monocentric Study of Oxaliplatin in Combination With Gemcitabine in Patients With Advanced/Metastatic Transitional Cell Carcinoma of the Urothelial Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <brief_summary>
    <textblock>
      This is a phase II monocentric study of oxaliplatin (Ox) in combination with gemcitabine
      (Gem; GEMOX) in patients (pts) with advanced/metastatic transitional cell carcinoma (TCC) of
      the urothelial tract.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2002</start_date>
  <completion_date>April 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate (Response Evaluation Criteria in Solid Tumors [RECIST] criteria)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
  </secondary_outcome>
  <enrollment>28</enrollment>
  <condition>Carcinoma, Transitional Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine, oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Transitional cell carcinoma

          -  Histologically-proven

          -  Locally advanced unresectable or metastatic

          -  With at least one measurable target

          -  Informed consent signed

        Exclusion Criteria:

          -  Previous chemotherapy

          -  Previous radiotherapy

          -  Performance status &gt;=2

          -  Peripheral neuropathy &gt;=1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine THEODORE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2005</study_first_submitted>
  <study_first_submitted_qc>August 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2005</study_first_posted>
  <last_update_submitted>August 23, 2005</last_update_submitted>
  <last_update_submitted_qc>August 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2005</last_update_posted>
  <keyword>carcinoma of the urothelial tract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

